|
1
|
Perazzo F, Piaggio F, Krupitzki H, et al:
Clinical-pathological features and gene profile in colorectal
cancer. Medicina (B Aires). 73:417–422. 2013.In Spanish.
|
|
2
|
Ahmed FE: Gene-gene, gene-environment
& multiple interactions in colorectal cancer. J Environ Sci
Health C Environ Carcinog Ecotoxicol Rev. 24:1–101. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel BB and Majumdar AP: Synergistic role
of curcumin with current therapeutics in colorectal cancer:
minireview. Nutr Cancer. 61:842–846. 2009. View Article : Google Scholar
|
|
4
|
Lerman MI and Minna JD: The 630-kb lung
cancer homozygous deletion region on human chromosome 3p21.3:
identification and evaluation of the resident candidate tumor
suppressor genes. Cancer Res. 60:6116–6133. 2000.PubMed/NCBI
|
|
5
|
Wistuba II, Behrens C, Virmani AK, Mele G,
et al: High resolution chromosome 3p allelotyping of human lung
cancer and preneoplastic/preinvasive bronchial epithelium reveals
multiple, discontinuous sites of 3p allele loss and three regions
of frequent breakpoints. Cancer Res. 60:1949–1960. 2000.PubMed/NCBI
|
|
6
|
Li J, Wang F, Haraldson K, Protopopov A,
et al: Functional characterization of the candidate tumor
suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res.
64:6438–6443. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schenk PW, Brok M, Boersma AW, et al:
Anticancer drug resistance induced by disruption of the
Saccharomyces cerevisiae NPR2 gene: a novel component involved in
cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol.
64:259–268. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ueda K, Kawashima H, Ohtani S, et al: The
3p21.3 tumor suppressor NPRL2 plays an important role in
cisplatin-induced resistance in human non-small-cell lung cancer
cells. Cancer Res. 66:9682–9690. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan AT and Giovannucci EL: Primary
prevention of colorectal cancer. Gastroenterology. 138:2029–2043.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Poynter JN, Haile RW, Siegmund KD, et al:
Colon Cancer Family Registry: Associations between smoking, alcohol
consumption and colorectal cancer, overall and by tumor
microsatellite instability status. Cancer Epidemiol Biomarkers
Prev. 18:2745–2750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bostick RM, Potter JD, Kushi LH, Sellers
TA, Steinmetz KA, McKenzie DR, Gapstur SM and Folsom AR: Sugar,
meat and fat intake and non-dietary risk factors for colon cancer
incidence in Iowa women (United States). Cancer Causes Control.
5:38–52. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, et al: Chronic oxaliplatin resistance induces
epithelial-to-mesenchymal transition in colorectal cancer cell
lines. Clin Cancer Res. 12:4147–4153. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shah AN, Summy JM, Zhang J, Park SI,
Parikh NU, et al: Development and characterization of
gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol.
14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De Larco JE, Wuertz BR, Manivel JC and
Furcht LT: Progression and enhancement of metastatic potential
after exposure of tumor cells to chemotherapeutic agents. Cancer
Res. 61:2857–2861. 2001.PubMed/NCBI
|
|
15
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, et al: Chemoresistance to paclitaxel induces
epithelial-mesenchymal transition and enhances metastatic potential
for epithelial ovarian carcinoma cells. Int J Oncol. 31:277–283.
2007.PubMed/NCBI
|
|
16
|
Xiong W, Ren ZG, Qiu SJ, Sun HC, Wang L,
et al: Residual hepatocellular carcinoma after oxaliplatin
treatment has increased metastatic potential in a nude mouse model
and is attenuated by Songyou Yin. BMC Cancer. 10:2192010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamauchi K, Yang M, Hayashi K, Jiang P,
Yamamoto N, et al: Induction of cancer metastasis by
cyclophosphamide pretreatment of host mice: an opposite effect of
chemotherapy. Cancer Res. 68:516–520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zabarovsky ER, Lerman MI and Minna JD:
Tumor suppressor genes on chromosome 3p involved in the
pathogenesis of lung and other cancers. Oncogene. 21:6915–6935.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ji L, Nishizaki M, Gao B, et al:
Expression of several genes in the human chromosome 3p21.3
homozygous deletion region by an adenovirus vector results in tumor
suppressor activities in vitro and in vivo. Cancer Res.
62:2715–2720. 2002.PubMed/NCBI
|
|
20
|
Zhou BB and Elledge SJ: The DNA damage
response: putting checkpoints in perspective. Nature. 408:433–439.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Johnson SM, Gulhati P, Rampy BA, Han Y,
Rychahou PG, Doan HQ, et al: Novel expression patterns of
PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J
Am Coll Surg. 210:767–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maira SM, Voliva C and Garcia-Echeverria
C: Class IA phosphatidylinositol 3-kinase: from their biologic
implication in human cancers to drug discovery. Expert Opin Ther
Targets. 12:223–238. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ekstrand AI, Jonsson M, Lindblom A, Borg A
and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways
in hereditary nonpolyposis colorectal cancer. Fam Cancer.
9:125–129. 2010. View Article : Google Scholar
|
|
24
|
Awasthi N, Yen PL, Schwarz MA and Schwarz
RE: The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to
enhance chemotherapy and antiangiogenic response in pancreatic
cancer. J Cell Biochem. 113:784–791. 2012. View Article : Google Scholar
|
|
25
|
Glienke W, Maute L, Wicht J and Bergmann
L: The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle
arrest and regulates Survivin gene expression in human pancreatic
cancer cell lines. Tumour Biol. 33:757–765. 2012. View Article : Google Scholar
|
|
26
|
Armegnol G, Rojo F, Castellví J, et al:
4E-binding protein 1: a key molecular ‘funnel factor’ in human
cancer with clinical implications. Cancer Res. 67:7551–7555. 2007.
View Article : Google Scholar
|
|
27
|
Xu G, Zhang W, Bertram P, et al:
Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in
common human tumors. Int J Oncol. 24:893–900. 2004.PubMed/NCBI
|
|
28
|
Lim SC and Oh SH: The role of CD24 in
various human epithelial neoplasias. Pathol Res Pract. 201:479–486.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sammar M, Aigner S, Hubbe M, Schirrmacher
V, Schachner M, Vestweber D and Altevogt P: Heat-stable antigen
(CD24) as ligand for mouse P-selectin. Int Immunol. 6:1027–1036.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aigner S, Ramos CL, Hafezi-Moghadam A,
Lawrence MB, Friederichs J, Altevogt P and Ley K: CD24 mediates
rolling of breast carcinoma cells on P-selectin. FASEB J.
12:1241–1251. 1998.PubMed/NCBI
|
|
31
|
Yong CS, Ou Yang CM, Chou YH, Liao CS, Lee
CW and Lee CC: CD44/CD24 expression in recurrent gastric cancer: A
retrospective analysis. BMC Gastroenterol. 12:952012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takahashi M, Nakajima M, Ogata H, Domeki
Y, Ohtsuka K, Ihara K, Kurayama E, Yamaguchi S, Sasaki K, Miyachi K
and Kato H: CD24 expression is associated with progression of
gastric cancer. Hepatogastroenterology. 60:653–658. 2013.
|
